We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Verve Therapeutics Inc (VERV) USD0.001

Sell:$5.26 Buy:$5.27 Change: $0.25 (4.45%)
NASDAQ:0.23%
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Sell:$5.26
Buy:$5.27
Change: $0.25 (4.45%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Sell:$5.26
Buy:$5.27
Change: $0.25 (4.45%)
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company’s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH). VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies.

Contact details

Address:
201 Brookline Avenue, Suite 601
BOSTON
02215
United States
Telephone:
+1 (978) 5013026
Website:
https://www.vervetx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
VERV
ISIN:
US92539P1012
Market cap:
$468.19 million
Shares in issue:
84.66 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Andrew Ashe
    President, Chief Operating Officer, General Counsel
  • Sekar Kathiresan
    Chief Executive Officer, Director
  • Allison Dorval
    Chief Financial Officer
  • Joan Nickerson
    Chief Administrative Officer
  • Troy Lister
    Chief Scientific Officer
  • Frederick Fiedorek
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.